Cargando…

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity

The microenvironment provides a functional substratum supporting tumour growth. Hyaluronan (HA) is a major component of this structure. While the role of HA in malignancy is well-defined, the mechanisms driving its biosynthesis in cancer are poorly understood. We show that the eukaryotic translation...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahreddine, Hiba Ahmad, Culjkovic-Kraljacic, Biljana, Emond, Audrey, Pettersson, Filippa, Midura, Ronald, Lauer, Mark, Del Rincon, Sonia, Cali, Valbona, Assouline, Sarit, Miller, Wilson H, Hascall, Vincent, Borden, Katherine LB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705209/
https://www.ncbi.nlm.nih.gov/pubmed/29111978
http://dx.doi.org/10.7554/eLife.29830
Descripción
Sumario:The microenvironment provides a functional substratum supporting tumour growth. Hyaluronan (HA) is a major component of this structure. While the role of HA in malignancy is well-defined, the mechanisms driving its biosynthesis in cancer are poorly understood. We show that the eukaryotic translation initiation factor eIF4E, an oncoprotein, drives HA biosynthesis. eIF4E stimulates production of enzymes that synthesize the building blocks of HA, UDP-Glucuronic acid and UDP-N-Acetyl-Glucosamine, as well as hyaluronic acid synthase which forms the disaccharide chain. Strikingly, eIF4E inhibition alone repressed HA levels as effectively as directly targeting HA with hyaluronidase. Unusually, HA was retained on the surface of high-eIF4E cells, rather than being extruded into the extracellular space. Surface-associated HA was required for eIF4E’s oncogenic activities suggesting that eIF4E potentiates an oncogenic HA program. These studies provide unique insights into the mechanisms driving HA production and demonstrate that an oncoprotein can co-opt HA biosynthesis to drive malignancy.